Palvella Therapeutics (NASDAQ:PVLA) Earns Buy Rating from Analysts at Stifel Nicolaus
Stifel Nicolaus assumed coverage on shares of Palvella Therapeutics (NASDAQ:PVLA – Free Report) in a research note published on Wednesday, Marketbeat reports. The firm issued a buy rating and a $45.00 price target on the stock. PVLA has been the subject of several other research reports. TD Cowen began coverage on shares of Palvella Therapeutics […]
Stifel Nicolaus assumed coverage on shares of Palvella Therapeutics (NASDAQ:PVLA – Free Report) in a research note published on Wednesday, Marketbeat reports. The firm issued a buy rating and a $45.00 price target on the stock. PVLA has been the subject of several other research reports. TD Cowen began coverage on shares of Palvella Therapeutics […]
